Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment ascophyllan
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature CCL19
Official Symbol CCL19
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Ascophyllan treatment led to marked increases in the proportion and number of DCs in spleen and tumor drLN. C-C chemokine receptor 7 (CCR7) expression levels, the marker of migrating DCs, in spleen DCs and tumor drLN and its ligands C-C motif ligand 19 (CCL19) and CCL21 in spleen were substantially increased by ascophyllan.
PMID 27008707
Title Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation